THC
Bearish signalScored 2026-09-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Tenet Healthcare Corporation
- Nom
- Tenet Healthcare Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NYSE
- Capitalisation
- $21.6B
- Employés
- 88,500
- PDG
- Saumya Sutaria
- Site web
- https://www.tenethealth.com
- Marché
- ARDTCONCYHFSNUYHCARMYHY
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services. These include core hospital functions such as operating and recovery suites, radiology and respiratory therapy, clinical laboratories, and on-site pharmacies. The organization also provides high-acuity patient care through intensive, critical, and coronary care units. Specialized medical services cover areas like cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics, alongside various outpatient treatments, including physical therapy. Advanced surgical capabilities feature cardiothoracic, complex spinal, and neurosurgery, as well as neonatal intensive care. Tenet extends its offerings to ultra-specialized quaternary care, exemplified by heart and kidney transplant programs, and sophisticated procedures such as limb-salvaging vascular interventions, acute Level 1 trauma care, intravascular stroke treatment, minimally invasive cardiac valve replacements, advanced imaging, and telemedicine access. Beyond its hospital network, Tenet manages numerous other clinical sites. These encompass outpatient surgical centers, immediate care facilities, diagnostic imaging centers, dedicated surgical hospitals, off-campus emergency departments, and micro-hospitals. Through its Conifer segment, the company furnishes critical healthcare business process solutions. These administrative services, offered to hospitals, health systems, physician practices, employers, and other clients, include financial administration for patient accounts (revenue cycle management), support for patient communications and engagement, and outcome-focused care strategies. As of February 9, 2022, Tenet's operational footprint included 60 hospitals and roughly 550 additional medical facilities. This count of additional sites comprises surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and various other clinical locations. Tenet Healthcare Corporation was established in 1975 and maintains its principal office in Dallas, Texas.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 132 484 titres (~36 138 216,30 $ US)
- Insiders
- KERREY J ROBERTMARK RICHARD JWest NadjaHANEY CECIL DSutaria SaumyaRomo TammyBlunt Roy
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$32,247,326
Avg sell (VWAP, 90d window) $265.97 vs last close $253.97 (-4.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-14
- Liquidity
- Liquid $193,531,870/day · 20d vol
- Last synced
-
2026-10-01 21:10:58
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | KERREY J ROBERT | Sell · S | 2,502 | $264.62 | $662,079 | Form 4 |
| 2026-09-10 | MARK RICHARD J | Sell · S | 10,000 | $263.42 | $2,634,200 | Form 4 |
| 2026-09-02 | West Nadja | Sell · S | 1,152 | $258.80 | $298,138 | Form 4 |
| 2026-08-31 | Foo Lisa Y | Sell · S | 24,000 | $266.32 | $6,391,680 | Form 4 |
| 2026-08-25 | Sutaria Saumya | Sell · S | 7,899 | $275.26 | $2,174,279 | Form 4 |
| 2026-08-24 | HANEY CECIL D | Sell · S | 1,300 | $278.03 | $361,439 | Form 4 |
| 2026-08-24 | Sutaria Saumya | Sell · S | 36,656 | $278.90 | $10,223,358 | Form 4 |
| 2026-08-07 | Romo Tammy | Sell · S | 2,500 | $260.83 | $652,075 | Form 4 |
| 2026-08-06 | Romo Tammy | Sell · S | 4,922 | $264.15 | $1,300,146 | Form 4 |
| 2026-08-05 | Blunt Roy | Sell · S | 600 | $262.68 | $157,608 | Form 4 |
| 2026-07-29 | Foo Lisa Y | Sell · S | 10,000 | $258.03 | $2,580,300 | Form 4 |
| 2026-07-27 | Arbour Paola M | Sell · S | 10,878 | $243.90 | $2,653,144 | Form 4 |
| 2026-07-27 | BIERMAN JAMES L | Sell · S | 5,000 | $244.96 | $1,224,800 | Form 4 |
| 2026-07-27 | Lynch Christopher S. | Sell · S | 3,837 | $243.44 | $934,079 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-04-20 | Jonathan Jackson | Sale (Full) | $15,001 - $50,000 |
| 2026-04-15 | Jonathan Jackson | Sale (Full) | $1,001 - $15,000 |
| 2026-02-11 | Jonathan Jackson | Sale (Partial) | $1,001 - $15,000 |
| 2025-12-10 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
| 2025-09-03 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-09-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
THC shows a solid liquidity profile and improved cash flow efficiency (liquidity score: 80), but the fundamental trend score (65) is weighed down by margin compression, high leverage, and heavy intangible asset exposure.
The first sentence of the analysis written for THC on 2026-09-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.76 · operating margin 16%
Suggested stop 249.77, nearest stored support minus 0.5 ATR(1.6% under the last close). Reward/risk to the next stored resistance is 4.83. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.3% | 39.7% | 38.0% | 36.8% | 37.3% | |
| Ebit Margin | 17.0% | 29.4% | 12.3% | 11.7% | 14.4% | |
| Ebitda Margin | 21.0% | 33.4% | 16.5% | 16.0% | 18.8% | |
| Operating Profit Margin | 16.1% | 28.8% | 12.2% | 12.2% | 14.7% | |
| Pretax Profit Margin | 13.1% | 25.4% | 7.9% | 7.0% | 9.7% | |
| Continuous Operations Profit Margin | 11.1% | 19.7% | 6.4% | 5.2% | 7.6% | |
| Net Profit Margin | 6.6% | 15.5% | 3.0% | 2.1% | 4.7% | |
| Bottom Line Profit Margin | 6.6% | 15.5% | 2.9% | 2.2% | 4.7% | |
| Current Ratio | 1.759 | 1.782 | 1.506 | 1.336 | 1.385 | |
| Quick Ratio | 1.681 | 1.702 | 1.419 | 1.246 | 1.310 | |
| Solvency Ratio | 0.110 | 0.197 | 0.065 | 0.056 | 0.076 | |
| Cash Ratio | 0.646 | 0.700 | 0.258 | 0.192 | 0.463 | |
| Price To Earnings Ratio | 12.730 | 3.823 | 12.574 | 12.706 | 9.554 | |
| Price To Earnings Growth Ratio | -0.241 | 0.009 | 0.223 | -0.231 | 0.076 | |
| Forward Price To Earnings Growth Ratio | -0.241 | 0.009 | 0.223 | -0.231 | 0.076 | |
| Price To Earnings Diluted Ratio | 12.829 | 3.860 | 13.235 | 12.873 | 9.702 | |
| Price To Earnings Diluted Growth Ratio | -0.244 | 0.008 | 0.261 | -0.234 | 0.078 | |
| Price To Book Ratio | 4.245 | 2.933 | 4.777 | 4.568 | 8.489 | |
| Price To Sales Ratio | 0.841 | 0.592 | 0.374 | 0.272 | 0.448 | |
| Price To Free Cash Flow Ratio | 7.081 | 10.961 | 4.733 | 16.253 | 9.590 | |
| Price To Operating Cash Flow Ratio | 5.061 | 5.976 | 3.235 | 4.817 | 5.566 | |
| Debt To Assets Ratio | 0.444 | 0.495 | 0.530 | 0.555 | 0.567 | |
| Debt To Equity Ratio | 3.121 | 3.435 | 9.330 | 13.204 | 15.220 | |
| Debt To Capital Ratio | 0.757 | 0.775 | 0.903 | 0.930 | 0.938 | |
| Long Term Debt To Capital Ratio | 0.756 | 0.753 | 0.902 | 0.929 | 0.938 | |
| Financial Leverage Ratio | 7.032 | 6.937 | 17.607 | 23.779 | 26.828 | |
| Working Capital Turnover Ratio | 6.307 | 7.152 | 10.505 | 11.048 | 9.135 | |
| Operating Cash Flow Ratio | 0.793 | 0.475 | 0.499 | 0.242 | 0.307 | |
| Operating Cash Flow Sales Ratio | 0.166 | 0.099 | 0.116 | 0.056 | 0.080 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.715 | 0.545 | 0.684 | 0.296 | 0.580 | |
| Debt Service Coverage Ratio | 4.501 | 5.087 | 3.019 | 2.640 | 3.077 | |
| Interest Coverage Ratio | 4.189 | 7.211 | 2.786 | 2.621 | 3.111 | |
| Short Term Operating Cash Flow Coverage Ratio | 44.810 | 6.916 | 19.783 | 7.469 | 11.615 | |
| Operating Cash Flow Coverage Ratio | 0.269 | 0.143 | 0.158 | 0.072 | 0.100 | |
| Capital Expenditure Coverage Ratio | 3.505 | 2.199 | 3.161 | 1.421 | 2.383 | |
| Dividend Paid And Capex Coverage Ratio | 3.505 | 2.199 | 3.161 | 1.421 | 2.383 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 6.290 | 3.416 | 6.333 | 6.319 | 6.004 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.3% | ▲42.5% | ▲35.5% |
| Ebit Margin | 17.0% | ▼-12.4% | ▲0.1% |
| Ebitda Margin | 21.0% | ▼-12.3% | ▼-0.1% |
| Operating Profit Margin | 16.1% | ▼-12.7% | ▼-0.7% |
| Pretax Profit Margin | 13.1% | ▼-12.3% | ▲0.5% |
| Continuous Operations Profit Margin | 11.1% | ▼-8.6% | ▲1.1% |
| Net Profit Margin | 6.6% | ▼-8.9% | ▲0.2% |
| Bottom Line Profit Margin | 6.6% | ▼-8.9% | ▲0.2% |
| Current Ratio | 1.759 | ▼-0.024 | ▲0.205 |
| Quick Ratio | 1.681 | ▼-0.021 | ▲0.209 |
| Solvency Ratio | 0.110 | ▼-0.087 | ▲0.009 |
| Cash Ratio | 0.646 | ▼-0.054 | ▲0.194 |
| Price To Earnings Ratio | 12.730 | ▲8.908 | ▲2.453 |
| Price To Earnings Growth Ratio | -0.241 | ▼-0.250 | ▼-0.208 |
| Forward Price To Earnings Growth Ratio | -0.241 | ▼-0.250 | ▼-0.208 |
| Price To Earnings Diluted Ratio | 12.829 | ▲8.969 | ▲2.329 |
| Price To Earnings Diluted Growth Ratio | -0.244 | ▼-0.252 | ▼-0.218 |
| Price To Book Ratio | 4.245 | ▲1.312 | ▼-0.757 |
| Price To Sales Ratio | 0.841 | ▲0.249 | ▲0.335 |
| Price To Free Cash Flow Ratio | 7.081 | ▼-3.880 | ▼-2.643 |
| Price To Operating Cash Flow Ratio | 5.061 | ▼-0.915 | ▲0.130 |
| Debt To Assets Ratio | 0.444 | ▼-0.051 | ▼-0.074 |
| Debt To Equity Ratio | 3.121 | ▼-0.314 | ▼-5.741 |
| Debt To Capital Ratio | 0.757 | ▼-0.017 | ▼-0.103 |
| Long Term Debt To Capital Ratio | 0.756 | ▲0.004 | ▼-0.099 |
| Financial Leverage Ratio | 7.032 | ▲0.095 | ▼-9.404 |
| Working Capital Turnover Ratio | 6.307 | ▼-0.845 | ▼-2.523 |
| Operating Cash Flow Ratio | 0.793 | ▲0.318 | ▲0.330 |
| Operating Cash Flow Sales Ratio | 0.166 | ▲0.067 | ▲0.063 |
| Free Cash Flow Operating Cash Flow Ratio | 0.715 | ▲0.170 | ▲0.151 |
| Debt Service Coverage Ratio | 4.501 | ▼-0.586 | ▲0.837 |
| Interest Coverage Ratio | 4.189 | ▼-3.022 | ▲0.205 |
| Short Term Operating Cash Flow Coverage Ratio | 44.810 | ▲37.895 | ▲26.692 |
| Operating Cash Flow Coverage Ratio | 0.269 | ▲0.126 | ▲0.120 |
| Capital Expenditure Coverage Ratio | 3.505 | ▲1.306 | ▲0.971 |
| Dividend Paid And Capex Coverage Ratio | 3.505 | ▲1.306 | ▲0.971 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 6.290 | ▲2.874 | ▲0.618 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $17.91B | $12.23B | $7.68B | $5.22B | $8.73B | |
| Enterprise value | $28.20B | $23.54B | $21.45B | $19.44B | $22.01B | |
| EV / Sales | 1.32x | 1.14x | 1.04x | 1.01x | 1.13x | |
| EV / Op. cash flow | 7.97x | 11.50x | 9.04x | 17.95x | 14.04x | |
| EV / Free cash flow | 11.15x | 21.09x | 13.22x | 60.55x | 24.19x | |
| EV / EBITDA | 6.29x | 3.42x | 6.33x | 6.32x | 6.00x | |
| Net debt / EBITDA | 2.29x | 1.64x | 4.07x | 4.62x | 3.62x | |
| Current ratio | 1.76x | 1.78x | 1.51x | 1.34x | 1.39x | |
| Income quality | 2.52x | 0.50x | 1.81x | 1.08x | 1.06x | |
| Graham number | $128 | $179 | $46 | $30 | $43 | |
| Graham net-net | -$174 | -$154 | -$185 | -$177 | -$171 | |
| Tax burden | 50.2% | 61.0% | 37.8% | 30.6% | 48.4% | |
| Interest burden | 77.3% | 86.4% | 64.2% | 60.2% | 67.2% | |
| Working capital | $3.39B | $3.37B | $2.41B | $1.50B | $1.97B | |
| Invested capital | $23.38B | $22.55B | $21.40B | $20.64B | $20.15B | |
| Return on assets | 4.7% | 11.1% | 2.2% | 1.5% | 3.3% | |
| Operating ROA | 11.7% | 20.8% | 9.1% | 8.5% | 10.5% | |
| Return on tangible assets | 8.2% | 19.0% | 3.7% | 2.6% | 5.4% | |
| Return on equity | 33.3% | 76.7% | 38.0% | 36.0% | 88.9% | |
| Return on invested capital | 11.5% | 18.5% | 8.6% | 7.6% | 9.9% | |
| Return on capital employed | 13.6% | 24.2% | 10.7% | 10.3% | 12.8% | |
| Earnings yield | 7.9% | 26.2% | 8.0% | 7.9% | 10.5% | |
| Free cash flow yield | 14.1% | 9.1% | 21.1% | 6.2% | 10.4% | |
| Capex / Op. cash flow | 28.5% | 45.5% | 31.6% | 70.4% | 42.0% | |
| Capex / Depreciation | 114.0% | 113.8% | 86.3% | 90.6% | 77.0% | |
| Capex / Sales | 4.7% | 4.5% | 3.7% | 4.0% | 3.4% | |
| SG&A / Sales | 40.8% | 42.6% | 2.0% | 2.1% | 2.1% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.5% | 0.3% | 0.3% | 0.3% | 0.3% | |
| Intangibles / Total assets | 42.3% | 41.8% | 41.2% | 42.5% | 39.0% | |
| Days sales outstanding | 44d | 54d | 60d | 66d | 62d | |
| Days payables outstanding | 131d | 38d | 40d | 45d | 39d | |
| Operating cycle | 78d | 64d | 72d | 78d | 73d | |
| Cash conversion cycle | -54d | 26d | 32d | 33d | 35d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-17 Tenet Healthcare (THC) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here''s why you should take advantage.
- 2026-09-17 Zacks Industry Outlook Tenet, Acadia and Community Health Systems Tenet, Acadia and Community Health Systems have been highlighted in this Industry Outlook article.
- 2026-09-16 3 Hospital Stocks Riding Strong Demand and Improved Efficiency The Zacks Medical-Hospital operators are benefiting from steady care demand while sharpening efficiency and portfolio strategy. Investors may want to track THC, ACHC and CYH.
- 2026-09-16 Are Investors Undervaluing Tenet Healthcare (THC) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 2026-09-16 Best Growth Stocks to Buy for September 16th THC, NESR and CNC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 16th, 2026.
- 2026-09-16 Best Value Stocks to Buy for September 16th PARR, KMT and THC made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 16th, 2026.
- 2026-09-16 Richard Mark Sells 10,000 Shares of Tenet Healthcare (NYSE:THC) Stock Tenet Healthcare Corporation (NYSE: THC - Get Free Report) Director Richard Mark sold 10,000 shares of the firm''s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $263.42, for a total transaction of $2,634,200.00. Following the transaction, the director directly owned 25,121 shares in the company,
- 2026-09-15 Tenet Healthcare (THC) Registers a Bigger Fall Than the Market: Important Facts to Note Tenet Healthcare (THC) closed the most recent trading day at $260.85, moving 1.38% from the previous trading session.
- 2026-09-15 Is Tenet (THC) a Solid Growth Stock? 3 Reasons to Think "Yes" Tenet (THC) possesses solid growth attributes, which could help it handily outperform the market.
- 2026-09-15 Wall Street Analysts Think Tenet (THC) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock''s price, do they really matter?